Compendium of Cancer Genome Aberrations

Changes

Volunteer Assignments and Opportunities (view source)

Revision as of 17:41, 21 May 2020

789 bytes added ,  17:41, 21 May 2020
no edit summary
Line 300: Line 300:  
|
 
|
 
|-
 
|-
−
|Acute  Undifferentiated Leukemia||Disease|| ||JH
+
|    Acute  Undifferentiated Leukemia||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease|| ||JH
+
|    Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| ||JH
+
|    ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| ||JH
+
|    ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| ||JH
 
|
 
|
 
|
 
|
Line 340: Line 340:  
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1     ||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA
 
|
 
|
 
|
 
|
Line 460: Line 460:  
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Plasma Cell Neoplasms||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Plasma Cell Myeloma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Plasma Cell Myeloma  Variants||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Plasmacytoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Monoclonal  Immunoglobulin Deposition Diseases||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|           Primary  Amyloidosis||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|           Light Chain  and Heavy Chain Deposition Disease||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome||'''''Overview'''''|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|         POEMS Syndrome||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|         TEMPI Syndrome||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Nodal Marginal Zone Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Follicular Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Testicular Follicular  Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    In Situ Follicular  Neoplasia||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Duodenal-Type  Follicular Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Paediatric-Type Follicular Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Primary Cutaneous Follicle Centre Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Mantle Cell Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|    In Situ Mantle Cell  Neoplasia||Disease|| ||SP
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
| || || ||
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||Greg Corboy (GC)
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example||Example|| ||GC
 
|
 
|
 
|
 
|
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/7929"